{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T02:23:03Z","timestamp":1788402183437,"version":"build-2803163510"},"update-to":[{"DOI":"10.1371\/journal.pmed.1004360","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2024,4,2]],"date-time":"2024-04-02T00:00:00Z","timestamp":1712016000000}}],"reference-count":46,"publisher":"Public Library of Science (PLoS)","issue":"3","license":[{"start":{"date-parts":[[2024,3,19]],"date-time":"2024-03-19T00:00:00Z","timestamp":1710806400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/publicdomain\/zero\/1.0\/"}],"funder":[{"DOI":"10.13039\/100006492","name":"Division of Intramural Research, National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["AI068614"],"award-info":[{"award-number":["AI068614"]}],"id":[{"id":"10.13039\/100006492","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006492","name":"Division of Intramural Research, National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["AI068635"],"award-info":[{"award-number":["AI068635"]}],"id":[{"id":"10.13039\/100006492","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006492","name":"Division of Intramural Research, National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["AI068618"],"award-info":[{"award-number":["AI068618"]}],"id":[{"id":"10.13039\/100006492","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006492","name":"Division of Intramural Research, National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["AI069501"],"award-info":[{"award-number":["AI069501"]}],"id":[{"id":"10.13039\/100006492","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006492","name":"Division of Intramural Research, National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["P30 AI064518"],"award-info":[{"award-number":["P30 AI064518"]}],"id":[{"id":"10.13039\/100006492","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006492","name":"Division of Intramural Research, National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["UM1 AI069453"],"award-info":[{"award-number":["UM1 AI069453"]}],"id":[{"id":"10.13039\/100006492","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006492","name":"Division of Intramural Research, National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["HHSN272201600012C"],"award-info":[{"award-number":["HHSN272201600012C"]}],"id":[{"id":"10.13039\/100006492","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["OPP1017604"],"award-info":[{"award-number":["OPP1017604"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosmedicine.org"],"crossmark-restriction":false},"short-container-title":["PLoS Med"],"abstract":"<jats:sec id=\"sec001\"><jats:title>Background<\/jats:title><jats:p>Adjuvants are widely used to enhance and\/or direct vaccine-induced immune responses yet rarely evaluated head-to-head. Our trial directly compared immune responses elicited by MF59 versus alum adjuvants in the RV144-like HIV vaccine regimen modified for the Southern African region. The RV144 trial of a recombinant canarypox vaccine vector expressing HIV<jats:italic>env<\/jats:italic>subtype B (ALVAC-HIV) prime followed by ALVAC-HIV plus a bivalent gp120 protein vaccine boost adjuvanted with alum is the only trial to have shown modest HIV vaccine efficacy. Data generated after RV144 suggested that use of MF59 adjuvant might allow lower protein doses to be used while maintaining robust immune responses. We evaluated safety and immunogenicity of an HIV recombinant canarypox vaccine vector expressing HIV<jats:italic>env<\/jats:italic>subtype C (ALVAC-HIV) prime followed by ALVAC-HIV plus a bivalent gp120 protein vaccine boost (gp120) adjuvanted with alum (ALVAC-HIV+gp120\/alum) or MF59 (ALVAC-HIV+gp120\/MF59) or unadjuvanted (ALVAC-HIV+gp120\/no-adjuvant) and a regimen where ALVAC-HIV+gp120 adjuvanted with MF59 was used for the prime and boost (ALVAC-HIV+gp120\/MF59 coadministration).<\/jats:p><\/jats:sec><jats:sec id=\"sec002\"><jats:title>Methods and findings<\/jats:title><jats:p>Between June 19, 2017 and June 14, 2018, 132 healthy adults without HIV in South Africa, Zimbabwe, and Mozambique were randomized to receive intramuscularly: (1) 2 priming doses of ALVAC-HIV (months 0 and 1) followed by 3 booster doses of ALVAC-HIV+gp120\/MF59 (months 3, 6, and 12),<jats:italic>n<\/jats:italic>= 36; (2) 2 priming doses of ALVAC-HIV (months 0 and 1) followed by 3 booster doses of ALVAC-HIV+gp120\/alum (months 3, 6, and 12),<jats:italic>n<\/jats:italic>= 36; (3) 4 doses of ALVAC-HIV+gp120\/MF59 coadministered (months 0, 1, 6, and 12),<jats:italic>n<\/jats:italic>= 36; or (4) 2 priming doses of ALVAC-HIV (months 0 and 1) followed by 3 booster doses of ALVAC-HIV+gp120\/no adjuvant (months 3, 6, and 12),<jats:italic>n<\/jats:italic>= 24. Primary outcomes were safety and occurrence and mean fluorescence intensity (MFI) of vaccine-induced gp120-specific IgG and IgA binding antibodies at month 6.5.<\/jats:p><jats:p>All vaccinations were safe and well-tolerated; increased alanine aminotransferase was the most frequent related adverse event, occurring in 2 (1.5%) participants (1 severe, 1 mild). At month 6.5, vaccine-specific gp120 IgG binding antibodies were detected in 100% of vaccinees for all 4 vaccine groups. No significant differences were seen in the occurrence and net MFI of vaccine-specific IgA responses between the ALVAC-HIV+gp120\/MF59-prime-boost and ALVAC-HIV+gp120\/alum-prime-boost groups or between the ALVAC-HIV+gp120\/MF59-prime-boost and ALVAC-HIV+gp120\/MF59 coadministration groups. Limitations were the relatively small sample size per group and lack of evaluation of higher gp120 doses.<\/jats:p><\/jats:sec><jats:sec id=\"sec003\"><jats:title>Conclusions<\/jats:title><jats:p>Although MF59 was expected to enhance immune responses, alum induced similar responses to MF59, suggesting that the choice between these adjuvants may not be critical for the ALVAC+gp120 regimen.<\/jats:p><\/jats:sec><jats:sec id=\"sec004\"><jats:title>Trial registration<\/jats:title><jats:p>HVTN 107 was registered with the South African National Clinical Trials Registry (<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/sanctr.samrc.ac.za\/Search_v2.aspx\" xlink:type=\"simple\">DOH-27-0715-4894<\/jats:ext-link>) and<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/clinicaltrials.gov\/\" xlink:type=\"simple\">ClinicalTrials.gov<\/jats:ext-link>(<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/clinicaltrials.gov\/ct2\/show\/NCT03284710\" xlink:type=\"simple\">NCT03284710<\/jats:ext-link>).<\/jats:p><\/jats:sec>","DOI":"10.1371\/journal.pmed.1004360","type":"journal-article","created":{"date-parts":[[2024,3,19]],"date-time":"2024-03-19T17:31:11Z","timestamp":1710869471000},"page":"e1004360","update-policy":"https:\/\/doi.org\/10.1371\/journal.pmed.corrections_policy","source":"Crossref","is-referenced-by-count":10,"title":["Safety and immunogenicity of a subtype C ALVAC-HIV (vCP2438) vaccine prime plus bivalent subtype C gp120 vaccine boost adjuvanted with MF59 or alum in healthy adults without HIV (HVTN 107): A phase 1\/2a randomized trial"],"prefix":"10.1371","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8701-2001","authenticated-orcid":true,"given":"Zoe","family":"Moodie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica","family":"Andersen-Nissen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2565-3879","authenticated-orcid":true,"given":"Nicole","family":"Grunenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5642-7121","authenticated-orcid":true,"given":"One B.","family":"Dintwe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faatima Laher","family":"Omar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia J.","family":"Kee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda-Gail","family":"Bekker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5231-9951","authenticated-orcid":true,"given":"Fatima","family":"Laher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8819-3825","authenticated-orcid":true,"given":"Nivashnee","family":"Naicker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6880-6655","authenticated-orcid":true,"given":"Ilesh","family":"Jani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nyaradzo M.","family":"Mgodi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6692-4378","authenticated-orcid":true,"given":"Portia","family":"Hunidzarira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Modulakgota","family":"Sebe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4637-1283","authenticated-orcid":true,"given":"Maurine D.","family":"Miner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5476-7632","authenticated-orcid":true,"given":"Laura","family":"Polakowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shelly","family":"Ramirez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Nebergall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6030-2359","authenticated-orcid":true,"given":"Simbarashe","family":"Takuva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lerato","family":"Sikhosana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3401-5935","authenticated-orcid":true,"given":"Jack","family":"Heptinstall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2009-3270","authenticated-orcid":true,"given":"Kelly E.","family":"Seaton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"De Rosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos A.","family":"Diazgranados","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4174-8424","authenticated-orcid":true,"given":"Marguerite","family":"Koutsoukos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0291-743X","authenticated-orcid":true,"given":"Olivier","family":"Van Der Meeren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan W.","family":"Barnett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9346-5485","authenticated-orcid":true,"given":"Niranjan","family":"Kanesa-thasan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James G.","family":"Kublin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgia D.","family":"Tomaras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Juliana","family":"McElrath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2179-2436","authenticated-orcid":true,"given":"Lawrence","family":"Corey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7847-3671","authenticated-orcid":true,"given":"Kathryn","family":"Mngadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Goepfert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the HVTN 107 Protocol Team","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2024,3,19]]},"reference":[{"issue":"9653","key":"pmed.1004360.ref001","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1016\/S0140-6736(08)61591-3","article-title":"Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial.","volume":"372","author":"SP Buchbinder","year":"2008","journal-title":"Lancet."},{"issue":"5","key":"pmed.1004360.ref002","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1086\/428404","article-title":"Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection","volume":"191","author":"NM Flynn","year":"2005","journal-title":"J Infect Dis"},{"issue":"7","key":"pmed.1004360.ref003","first-page":"507","article-title":"Safety and efficacy of the HVTN 503\/Phambili study of a clade-B-based HIV-1 vaccine","volume":"11","author":"GE Gray","year":"2011","journal-title":"South Africa: a double-blind"},{"issue":"12","key":"pmed.1004360.ref004","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1056\/NEJMoa2031499","article-title":"Vaccine Efficacy of ALVAC-HIV and Bivalent Subtype C gp120-MF59 in Adults","volume":"384","author":"GE Gray","year":"2021","journal-title":"N Engl J Med"},{"key":"pmed.1004360.ref005","first-page":"2022","article-title":"editors. Phase IIb Efficacy Trial of Mosaic Hiv-1 Vaccine Regimen in African Women: Imbokodo.","author":"GE Gray","year":"2022","journal-title":"Conference of Retroviruses and Opportunistic Infections"},{"issue":"22","key":"pmed.1004360.ref006","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1056\/NEJMoa1310566","article-title":"Efficacy trial of a DNA\/rAd5 HIV-1 preventive vaccine","volume":"369","author":"SM Hammer","year":"2013","journal-title":"N Engl J Med"},{"issue":"12","key":"pmed.1004360.ref007","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1086\/508748","article-title":"Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand","volume":"194","author":"P Pitisuttithum","year":"2006","journal-title":"J Infect Dis"},{"issue":"23","key":"pmed.1004360.ref008","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa0908492","article-title":"Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand","volume":"361","author":"S Rerks-Ngarm","year":"2009","journal-title":"N Engl J Med"},{"issue":"7","key":"pmed.1004360.ref009","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/S1473-3099(12)70088-9","article-title":"Risk behaviour and time as covariates for efficacy of the HIV vaccine regimen ALVAC-HIV (vCP1521) and AIDSVAX B\/E: a post-hoc analysis of the Thai phase 3 efficacy trial RV 144.","volume":"12","author":"ML Robb","year":"2012","journal-title":"Lancet Infect Dis."},{"issue":"6","key":"pmed.1004360.ref010","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1097\/COH.0000000000000322","article-title":"Pox-Protein Public Private Partnership program and upcoming HIV vaccine efficacy trials","volume":"11","author":"ND Russell","year":"2016","journal-title":"Curr Opin HIV AIDS"},{"issue":"7","key":"pmed.1004360.ref011","doi-asserted-by":"crossref","first-page":"e366","DOI":"10.1016\/S2352-3018(18)30071-7","article-title":"Subtype C ALVAC-HIV and bivalent subtype C gp120\/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1\/2 trial.","volume":"5","author":"LG Bekker","year":"2018","journal-title":"Lancet HIV."},{"issue":"3","key":"pmed.1004360.ref012","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1097\/COH.0000000000000365","article-title":"Adjuvants: tailoring humoral immune responses","volume":"12","author":"MJ McElrath","year":"2017","journal-title":"Curr Opin HIV AIDS"},{"issue":"7","key":"pmed.1004360.ref013","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1038\/nm.4105","article-title":"Adjuvant-dependent innate and adaptive immune signatures of risk of SIVmac251 acquisition","volume":"22","author":"M Vaccari","year":"2016","journal-title":"Nat Med"},{"issue":"3","key":"pmed.1004360.ref014","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1128\/JVI.02544-12","article-title":"Antibodies with high avidity to the gp120 envelope protein in protection from simian immunodeficiency virus SIV(mac251) acquisition in an immunization regimen that mimics the RV-144 Thai trial.","volume":"87","author":"P Pegu","year":"2013","journal-title":"J Virol"},{"issue":"7","key":"pmed.1004360.ref015","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.4049\/jimmunol.1600674","article-title":"Boosting of ALVAC-SIV Vaccine-Primed Macaques with the CD4-SIVgp120 Fusion Protein Elicits Antibodies to V2 Associated with a Decreased Risk of SIVmac251 Acquisition.","volume":"197","author":"SN Gordon","year":"2016","journal-title":"J Immun."},{"key":"pmed.1004360.ref016","doi-asserted-by":"crossref","first-page":"6565","DOI":"10.1038\/ncomms7565","article-title":"Analysis of immunoglobulin transcripts and hypermutation following SHIV(AD8) infection and protein-plus-adjuvant immunization.","volume":"6","author":"JR Francica","year":"2015","journal-title":"Nat Commun."},{"issue":"11","key":"pmed.1004360.ref017","doi-asserted-by":"crossref","first-page":"e737","DOI":"10.1016\/S2352-3018(19)30262-0","article-title":"Safety and immunogenicity of a multivalent HIV vaccine comprising envelope protein with either DNA or NYVAC vectors (HVTN 096): a phase 1b, double-blind, placebo-controlled trial.","volume":"6","author":"G Pantaleo","year":"2019","journal-title":"Lancet HIV."},{"issue":"36","key":"pmed.1004360.ref018","doi-asserted-by":"crossref","first-page":"3747","DOI":"10.1016\/j.vaccine.2013.04.037","article-title":"HIV\/SIV DNA vaccine combined with protein in a co-immunization protocol elicits highest humoral responses to envelope in mice and macaques","volume":"31","author":"J Li","year":"2013","journal-title":"Vaccine"},{"issue":"4","key":"pmed.1004360.ref019","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.vaccine.2013.11.022","article-title":"Improvement of antibody responses by HIV envelope DNA and protein co-immunization","volume":"32","author":"F Pissani","year":"2014","journal-title":"Vaccine"},{"key":"pmed.1004360.ref020","first-page":"9","article-title":"Vaccine priming is restricted to draining lymph nodes and controlled by adjuvant-mediated antigen uptake","author":"F Liang","year":"2017","journal-title":"Sci Transl Med"},{"issue":"14","key":"pmed.1004360.ref021","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1056\/NEJMoa1113425","article-title":"Immune-correlates analysis of an HIV-1 vaccine efficacy trial","volume":"366","author":"BF Haynes","year":"2012","journal-title":"N Engl J Med"},{"issue":"2","key":"pmed.1004360.ref022","doi-asserted-by":"crossref","first-page":"e87572","DOI":"10.1371\/journal.pone.0087572","article-title":"Vaccine-induced IgG antibodies to V1V2 regions of multiple HIV-1 subtypes correlate with decreased risk of HIV-1 infection.","volume":"9","author":"S Zolla-Pazner","year":"2014","journal-title":"PLoS ONE."},{"issue":"228","key":"pmed.1004360.ref023","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3007730","article-title":"Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccination.","volume":"6","author":"NL Yates","year":"2014","journal-title":"Sci Transl Med."},{"issue":"13","key":"pmed.1004360.ref024","first-page":"1227","article-title":"Expanding Efforts and Support to Respond to the HIV and COVID-19","volume":"327","author":"L Corey","year":"2022","journal-title":"Intersecting Pandemics. JAMA"},{"issue":"1","key":"pmed.1004360.ref025","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jim.2007.03.002","article-title":"Optimization and validation of an 8-color intracellular cytokine staining (ICS) assay to quantify antigen-specific T cells induced by vaccination.","volume":"323","author":"H Horton","year":"2007","journal-title":"J Immunol Methods"},{"key":"pmed.1004360.ref026","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jim.2013.11.022","article-title":"Optimization and validation of the TZM-bl assay for standardized assessments of neutralizing antibodies against HIV-1","volume":"409","author":"M Sarzotti-Kelsoe","year":"2014","journal-title":"J Immunol Methods"},{"issue":"24","key":"pmed.1004360.ref027","doi-asserted-by":"crossref","first-page":"12449","DOI":"10.1128\/JVI.01708-08","article-title":"Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia.","volume":"82","author":"GD Tomaras","year":"2008","journal-title":"J Virol"},{"issue":"22","key":"pmed.1004360.ref028","doi-asserted-by":"crossref","first-page":"9019","DOI":"10.1073\/pnas.1301456110","article-title":"Vaccine-induced plasma IgA specific for the C1 region of the HIV-1 envelope blocks binding and effector function of IgG","volume":"110","author":"GD Tomaras","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"pmed.1004360.ref029","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1038\/nbt.3187","article-title":"COMPASS identifies T-cell subsets correlated with clinical outcomes","volume":"33","author":"L Lin","year":"2015","journal-title":"Nat Biotechnol"},{"issue":"1","key":"pmed.1004360.ref030","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1198\/sbr.2009.0008","article-title":"Simultaneous Evaluation of the Magnitude and Breadth of a Left and Right Censored Multivariate Response, with Application to HIV Vaccine Development","volume":"1","author":"Y Huang","year":"2009","journal-title":"Stat Biopharm Res"},{"issue":"2","key":"pmed.1004360.ref031","first-page":"119","article-title":"Approximate Is Better than \u201cExact\u201d for Interval Estimation of Binomial Proportions.","volume":"52","author":"A Agresti","year":"1998","journal-title":"Amer Statist"},{"issue":"12","key":"pmed.1004360.ref032","doi-asserted-by":"crossref","first-page":"e1008121","DOI":"10.1371\/journal.ppat.1008121","article-title":"ALVAC-HIV B\/C candidate HIV vaccine efficacy dependent on neutralization profile of challenge virus and adjuvant dose and type","volume":"15","author":"L Schifanella","year":"2019","journal-title":"PLoS Pathog"},{"issue":"25","key":"pmed.1004360.ref033","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1182\/bloodadvances.2017011411","article-title":"Innate transcriptional effects by adjuvants on the magnitude, quality, and durability of HIV envelope responses","volume":"1","author":"JR Francica","year":"2017","journal-title":"NHPs. Blood Adv"},{"issue":"12","key":"pmed.1004360.ref034","doi-asserted-by":"crossref","first-page":"6172","DOI":"10.4049\/jimmunol.1401504","article-title":"Antibody to the gp120 V1\/V2 loops and CD4+ and CD8+ T cell responses in protection from SIVmac251 vaginal acquisition and persistent viremia.","volume":"193","author":"SN Gordon","year":"2014","journal-title":"J Immun."},{"issue":"11","key":"pmed.1004360.ref035","doi-asserted-by":"crossref","first-page":"4838","DOI":"10.1172\/JCI126391","article-title":"Antibody Fc effector functions and IgG3 associate with decreased HIV-1 risk","volume":"129","author":"SD Neidich","year":"2019","journal-title":"J Clin Invest"},{"issue":"1","key":"pmed.1004360.ref036","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/s41541-022-00514-9","article-title":"Impact of adjuvants on the biophysical and functional characteristics of HIV vaccine-elicited antibodies in humans.","volume":"7","author":"S Xu","year":"2022","journal-title":"NPJ Vaccines."},{"issue":"5","key":"pmed.1004360.ref037","doi-asserted-by":"crossref","first-page":"e1003117","DOI":"10.1371\/journal.pmed.1003117","article-title":"Antibody and cellular responses to HIV vaccine regimens with DNA plasmid as compared with ALVAC priming: An analysis of two randomized controlled trials","volume":"17","author":"Z Moodie","year":"2020","journal-title":"PLoS Med"},{"key":"pmed.1004360.ref038","first-page":"198","article-title":"Antigenic competition affects the magnitude and breadth of CD8 T cell immunity following immunization with a nanoparticle neoantigen cancer vaccine","author":"NJ Blobel","year":"2017","journal-title":"J Immun"},{"issue":"4","key":"pmed.1004360.ref039","doi-asserted-by":"crossref","first-page":"e34723","DOI":"10.1371\/journal.pone.0034723","article-title":"Altering an artificial Gagpolnef polyprotein and mode of ENV co-administration affects the immunogenicity of a clade C HIV DNA vaccine","volume":"7","author":"K Bockl","year":"2012","journal-title":"PLoS ONE"},{"issue":"519","key":"pmed.1004360.ref040","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaw1673","article-title":"Antigenic competition in CD4(+) T cell responses in a randomized, multicenter, double-blind clinical HIV vaccine trial.","volume":"11","author":"EG Kallas","year":"2019","journal-title":"Sci Transl Med."},{"issue":"8","key":"pmed.1004360.ref041","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1080\/21645515.2015.1016671","article-title":"Dose-dependent inhibition of Gag cellular immunity by Env in SIV\/HIV DNA vaccinated macaques","volume":"11","author":"A Valentin","year":"2015","journal-title":"Hum Vaccin Immunother"},{"issue":"1","key":"pmed.1004360.ref042","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1093\/cid\/ciz1239","article-title":"Phase 1 Human Immunodeficiency Virus (HIV) Vaccine Trial to Evaluate the Safety and Immunogenicity of HIV Subtype C DNA and MF59-Adjuvanted Subtype C Envelope Protein.","volume":"72","author":"MC Hosseinipour","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"11","key":"pmed.1004360.ref043","doi-asserted-by":"crossref","first-page":"4769","DOI":"10.1172\/JCI128699","article-title":"DNA priming and gp120 boosting induces HIV-specific antibodies in a randomized clinical trial","volume":"129","author":"NG Rouphael","year":"2019","journal-title":"J Clin Invest"},{"issue":"10","key":"pmed.1004360.ref044","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1038\/s41590-021-01026-9","article-title":"The transcription factor CREB1 is a mechanistic driver of immunogenicity and reduced HIV-1 acquisition following ALVAC vaccination","volume":"22","author":"JA Tomalka","year":"2021","journal-title":"Nat Immunol"},{"issue":"4","key":"pmed.1004360.ref045","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1086\/422258","article-title":"Safety and immunogenicity of an HIV subtype B and E prime-boost vaccine combination in HIV-negative Thai adults","volume":"190","author":"S Nitayaphan","year":"2004","journal-title":"J Infect Dis"},{"issue":"8","key":"pmed.1004360.ref046","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01843-17","article-title":"HIV-1 Envelope Glycoproteins from Diverse Clades Differentiate Antibody Responses and Durability among Vaccinees","volume":"92","author":"NL Yates","year":"2018","journal-title":"J Virol"}],"updated-by":[{"DOI":"10.1371\/journal.pmed.1004360","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2024,4,2]],"date-time":"2024-04-02T00:00:00Z","timestamp":1712016000000}}],"container-title":["PLOS Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pmed.1004360","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T16:48:14Z","timestamp":1731602894000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pmed.1004360"}},"subtitle":[],"editor":[{"given":"Marie-Louise","family":"Newell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2024,3,19]]},"references-count":46,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,3,19]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pmed.1004360","relation":{"new_version":[{"id-type":"doi","id":"10.1371\/journal.pmed.1004360","asserted-by":"object"}]},"ISSN":["1549-1676"],"issn-type":[{"value":"1549-1676","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,19]]}}}